To assess whether and how ARBs restore impaired insulin signaling, we treated HepG2 cells for 16 h with 0.5 mM PA and three concentrations (5–20 μM) of nine FDA-approved ARBs that are commonly prescribed to treat hypertension in human patients. The gene discussed is INS; the disease is hypertensive disorder.